Benitec Biopharma (BNTC) Cash from Operations (2019 - 2025)

Benitec Biopharma has reported Cash from Operations for 7 years, with the latest figure at 3700000.0 in Q4 2025.

• Quarterly Cash from Operations rose 51.97% year-over-year to 3700000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 18411000.0 (up 15.5% YoY) and the FY2025 annual result came in at 23600000.0, down 21.65% from the prior year.
• Cash from Operations declined to 3700000.0 in Q4 2025 per BNTC's latest filing, from 3400000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 1989000.0 in Q1 2021 and troughed at 8225000.0 in Q2 2025.
• A 5-year average of 4557300.0 and a median of 4191500.0 in 2021 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2021 and 2025: Cash from Operations sank 158.65% in 2021, then surged 51.97% in 2025.
• Over 5 years, Cash from Operations stood at 3300000.0 in 2021, then slumped by 77.42% to 5855000.0 in 2022, then increased by 9.48% to 5300000.0 in 2023, then plunged by 45.34% to 7703000.0 in 2024, then soared by 51.97% to 3700000.0 in 2025.
• According to Business Quant data, Cash from Operations over the past three periods registered 3700000.0, 3400000.0, and 8225000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.